S&P 500 4,967.23

DOW 37,986.40

QQQ 414.65

How major US stock indexes fared Friday, 4/19/2024

SHOCKING Crypto Leak… (Ad)

Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week

American Express profits jump 34%, helped by jump in new customers, higher spending

A.I. Pioneer Issues Urgent Warning to Americans (Ad)

American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024

Intuitive Surgical Stock Can Trend Much Higher This Year

Secret Bull Market Starts in This Unusual Sector (Ad)

3 Magnificent Seven Stocks Outperforming the Rest

Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

S&P 500 4,967.23

DOW 37,986.40

QQQ 414.65

How major US stock indexes fared Friday, 4/19/2024

SHOCKING Crypto Leak… (Ad)

Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week

American Express profits jump 34%, helped by jump in new customers, higher spending

A.I. Pioneer Issues Urgent Warning to Americans (Ad)

American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024

Intuitive Surgical Stock Can Trend Much Higher This Year

Secret Bull Market Starts in This Unusual Sector (Ad)

3 Magnificent Seven Stocks Outperforming the Rest

Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

S&P 500 4,967.23

DOW 37,986.40

QQQ 414.65

How major US stock indexes fared Friday, 4/19/2024

SHOCKING Crypto Leak… (Ad)

Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week

American Express profits jump 34%, helped by jump in new customers, higher spending

A.I. Pioneer Issues Urgent Warning to Americans (Ad)

American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024

Intuitive Surgical Stock Can Trend Much Higher This Year

Secret Bull Market Starts in This Unusual Sector (Ad)

3 Magnificent Seven Stocks Outperforming the Rest

Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

S&P 500 4,967.23

DOW 37,986.40

QQQ 414.65

How major US stock indexes fared Friday, 4/19/2024

SHOCKING Crypto Leak… (Ad)

Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week

American Express profits jump 34%, helped by jump in new customers, higher spending

A.I. Pioneer Issues Urgent Warning to Americans (Ad)

American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024

Intuitive Surgical Stock Can Trend Much Higher This Year

Secret Bull Market Starts in This Unusual Sector (Ad)

3 Magnificent Seven Stocks Outperforming the Rest

Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Free Trial

Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

No chart data

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PFNX Pfenex	$12.75	$0.00	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PFNX Pfenex	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PFNX Pfenex	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
PFNX Pfenex	N/A

Insider Ownership

Company	Insider Ownership
PFNX Pfenex	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
PFNX Pfenex	71	34.30 million	N/A	Not Optionable

PFNX and TILS Headlines

Source	Headline
	NKY Medical Holdings Ltd Class A 300109 morningstar.com - January 31 at 6:39 PM
	Last available seats at PFS West Coast Conference next week pharmaphorum.com - May 19 at 6:04 PM
	Ligand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best Stocks news.google.com - May 4 at 7:30 PM
	150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal news.google.com - April 13 at 12:19 AM
	Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio - Nasdaq news.google.com - April 6 at 5:35 PM
	LENZ Therapeutics Closes $83.5M Series B - San Diego Business Journal news.google.com - March 29 at 1:06 PM
	Ranibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital Journal news.google.com - March 17 at 10:21 AM
	Global Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswire news.google.com - March 15 at 8:24 PM
	San Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-Tribune news.google.com - March 15 at 8:24 PM
	Osteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital Journal news.google.com - March 13 at 7:40 AM
	Current and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPR news.google.com - March 1 at 11:39 AM
	Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield Californian news.google.com - February 23 at 5:24 PM
	Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - Business Wire news.google.com - February 22 at 5:46 PM
	Biosimilar Growth Hormones Global Market Report 2023 - Yahoo Finance news.google.com - February 8 at 4:13 PM
	Biosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo Finance news.google.com - February 8 at 4:13 PM
	Osteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital Journal news.google.com - February 7 at 3:49 AM
	Injectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.com news.google.com - January 27 at 9:00 PM
	Osteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital Journal news.google.com - January 27 at 9:34 AM
	Injectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPR news.google.com - January 6 at 1:28 PM
	Abzena Names Matthew Stober CEO - Contract Pharma news.google.com - January 5 at 2:36 PM
	Abzena hires Matthew Stober to lead the company through the next ... - Bio-IT World news.google.com - January 4 at 5:54 PM
	Osteoporosis Treatment Market Will Reflect Significant Growth Prospects during 2022 – 2028 \| Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED. - Digital Journal news.google.com - December 7 at 8:29 AM
	Ligand Reports Third Quarter 2022 Financial Results - StreetInsider.com news.google.com - November 8 at 4:47 AM
	Krystal Biotech Stock: A Buy For Growth Potential (NASDAQ:KRYS) - Seeking Alpha news.google.com - November 6 at 2:43 AM

Company Descriptions

Pfenex

NYSEAMERICAN:PFNX

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Compare Stocks

Compare Stocks - Price & Volume

MarketRank™

Analyst Ratings

Sales & Book Value

Profitability & Earnings

Dividends

Ownership

Institutional Ownership

Insider Ownership

Miscellaneous

PFNX and TILS Headlines

Company Descriptions

Pfenex

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info